IR@PKUHSC  > 北京大学精神卫生研究所
学科主题精神卫生
Pharmacokinetics and Tolerability of Extended-Release Quetiapine Fumarate in Han Chinese Patients with Schizophrenia
Li, Qian1; Su, Yun Ai1; Liu, Yi1; Chen, Jing Xu2; Tan, Yun Long2; Yang, Fu De2; Si, Tian Mei1
刊名CLINICAL PHARMACOKINETICS
2014-05-01
DOI10.1007/s40262-013-0127-9
53期:5页:455-465
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Pharmacology & Pharmacy
资助者AstraZeneca Pharmaceutical Research Development ; AstraZeneca Pharmaceutical Research Development
研究领域[WOS]Pharmacology & Pharmacy
关键词[WOS]REPORTED SEDATION PROFILE ; DOUBLE-BLIND ; IMMEDIATE-RELEASE ; PLASMA-CONCENTRATIONS ; N-DESALKYLQUETIAPINE ; BIPOLAR DISORDER ; SEX-DIFFERENCES ; HUMAN LIVER ; EFFICACY ; PLACEBO
英文摘要

Background and Objective The extended-release formulation of quetiapine (quetiapine XR), which was developed to provide more convenient once-daily administration, has been widely studied to characterize its pharmacokinetics in Caucasian populations but has rarely been studied in an Asia population. This study was conducted to evaluate the pharmacokinetics and tolerability of quetiapine XR administered as a single dose (300 mg) and multiple doses (300, 600, and 800 mg) in Han Chinese patients with schizophrenia.

Methods This was a single-center, open-label, single-dose and multiple-dose randomized study. Among the 55 randomized subjects, a total of 40 female or male patients in 300 mg (n = 13), 600 mg (n = 13), or 800 mg (n = 14) groups completed the study of quetiapine fumarate XR. The treatment phase consisted of 5 consecutive days and was preceded by a 1- to 2-day titration period for the 600 and 800 mg groups. Pharmacokinetic parameters for both quetiapine and N-desalkyl quetiapine (norquetiapine) were determined. The tolerability evaluation included adverse events (AEs) noted by monitoring, physical examinations, vital signs, and clinical laboratory tests.

Results N-desalkyl quetiapine was formed from quetiapine with an approximate metabolite to parent ratio of 0.5 across the three dose groups. The geometric mean elimination half-life (t (A1/2)) of both quetiapine and N-desalkyl quetiapine was consistent for the three dosing groups (approximately 7 h for quetiapine and approximately 18 h for N-desalkyl quetiapine). The geometric mean maximum plasma concentrations (C (max)) at steady state (C (max,ss)) of quetiapine for the three groups were 467, 740, and 1,126 ng/mL, respectively, and for N-desalkyl quetiapine were 138, 262, and 426 ng/mL, respectively. The values for the geometric mean area under the plasma concentration-time curve over a dosing interval at the steady-state (AUC(ss)) of quetiapine were 5,094, 7,685, and 13,237 ng center dot h/mL, respectively, and for N-desalkyl quetiapine were 2,284, 4,341, and 7,216 ng center dot h/mL, respectively. The apparent oral clearance (CL/F) of quetiapine at steady state appeared to be comparable across the three dose groups. The pharmacokinetics of quetiapine XR were dose-proportional across the dosage range employed. The most common AE was somnolence, but all of the reported AEs were mild. There were no serious AEs or other significant AEs.

Conclusion Quetiapine fumarate XR has a dose-proportional pharmacokinetic profile at doses ranging from 300 to 800 mg once daily, and a slower time to reach C (max) and steady state after 3 days of sequential dosing. Therefore, it offers a simple and rapid dose-escalation option and more convenient once-daily administration. The three dosages of quetiapine fumarate XR were generally well-tolerated in this pharmacokinetic study of Han Chinese patients with schizophrenia.

语种英语
资助者AstraZeneca Pharmaceutical Research Development ; AstraZeneca Pharmaceutical Research Development
WOS记录号WOS:000335144000004
Citation statistics
Cited Times:2[WOS]   [WOS Record]     [Related Records in WOS]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/51691
Collection北京大学精神卫生研究所
作者单位1.Beijing Huilongguan Hosp, Ctr Psychiat Res, Beijing, Peoples R China
2.Peking Univ, Dept Clin Psychopharmacol, Inst Mental Hlth, Key Lab Mental Hlth,Minist Hlth, Beijing 100191, Peoples R China
Recommended Citation
GB/T 7714
Li, Qian,Su, Yun Ai,Liu, Yi,et al. Pharmacokinetics and Tolerability of Extended-Release Quetiapine Fumarate in Han Chinese Patients with Schizophrenia[J]. CLINICAL PHARMACOKINETICS,2014,53(5):455-465.
APA Li, Qian.,Su, Yun Ai.,Liu, Yi.,Chen, Jing Xu.,Tan, Yun Long.,...&Si, Tian Mei.(2014).Pharmacokinetics and Tolerability of Extended-Release Quetiapine Fumarate in Han Chinese Patients with Schizophrenia.CLINICAL PHARMACOKINETICS,53(5),455-465.
MLA Li, Qian,et al."Pharmacokinetics and Tolerability of Extended-Release Quetiapine Fumarate in Han Chinese Patients with Schizophrenia".CLINICAL PHARMACOKINETICS 53.5(2014):455-465.
Files in This Item:
There are no files associated with this item.
Related Services
Recommend this item
Bookmark
Usage statistics
Export to Endnote
谷歌学术
谷歌学术Similar articles in
[Li, Qian]'s Articles
[Su, Yun Ai]'s Articles
[Liu, Yi]'s Articles
百度学术
百度学术Similar articles in
[Li, Qian]'s Articles
[Su, Yun Ai]'s Articles
[Liu, Yi]'s Articles
必应学术
必应学术Similar articles in
[Li, Qian]'s Articles
[Su, Yun Ai]'s Articles
[Liu, Yi]'s Articles
Terms of Use
No data!
Social Bookmark/Share
All comments (0)
No comment.
 

Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.